Use of dianhydrogalactitol and analogs and derivatives thereof to treat glioblastoma multiforme
US9687466B2 · kind B2 · utility
4Cited by
38References
42Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 4, 2014 |
| Grant date | Jun 27, 2017 |
| Priority date | — |
| Expiry date | Apr 16, 2034 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.